



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Tovetumab

Cat. No.:	HY-P99223
CAS No.:	1243266-04-7
Target:	PDGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Tovetumab (MEDI-575) is an anti-PDGFR $\alpha$ monoclonal antibody that selectively blocks the PDGFR $\alpha$ signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) <sup>[1][2]</sup> .																	
<b>IC<sub>50</sub> &amp; Target</b>	PDGFR $\alpha$																	
<b>In Vitro</b>	Tovetumab (10-100 nM, 1-2 h) binds to PDGFR $\alpha$ on H1703 cells (determined by Alexa647-labeled tovetumab) <sup>[1]</sup> . Tovetumab (0.001-10 nM, 10 min) inhibits ligand-induced phosphorylation of human PDGFR $\alpha$ in MG-63 cells <sup>[2]</sup> . Tovetumab (0.001-100 nM, 72 h) inhibits Ligand-induced proliferation of cancer-associated fibroblasts (CAFs) <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																	
<b>In Vivo</b>	<p>Tovetumab (0.6-60 mg/kg, i.v.) blocks the PDGFR<math>\alpha</math>-mediated elimination of PDGF-AA, leading to an increase in circulating PDGF-AA level in Cynomolgus monkeys<sup>[1]</sup>.</p> <p>Tovetumab (10 mg/kg, i.p., twice a week) inhibits tumor growth in U118 glioma xenografts<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Cynomolgus monkey<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.6, 6.0, and 60 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection (i.v.)</td> </tr> <tr> <td>Result:</td> <td>Induced &gt; 100- fold increases in circulating concentrations of PDGF-AA.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>U118 glioma xenografts (CB17 SCID)<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection (i.p.), twice per week.</td> </tr> <tr> <td>Result:</td> <td>Produced 101% inhibition of tumor growth.</td> </tr> </table>		Animal Model:	Cynomolgus monkey <sup>[1]</sup>	Dosage:	0.6, 6.0, and 60 mg/kg	Administration:	Intravenous injection (i.v.)	Result:	Induced > 100- fold increases in circulating concentrations of PDGF-AA.	Animal Model:	U118 glioma xenografts (CB17 SCID) <sup>[2]</sup>	Dosage:	10 mg/kg	Administration:	Intraperitoneal injection (i.p.), twice per week.	Result:	Produced 101% inhibition of tumor growth.
Animal Model:	Cynomolgus monkey <sup>[1]</sup>																	
Dosage:	0.6, 6.0, and 60 mg/kg																	
Administration:	Intravenous injection (i.v.)																	
Result:	Induced > 100- fold increases in circulating concentrations of PDGF-AA.																	
Animal Model:	U118 glioma xenografts (CB17 SCID) <sup>[2]</sup>																	
Dosage:	10 mg/kg																	
Administration:	Intraperitoneal injection (i.p.), twice per week.																	
Result:	Produced 101% inhibition of tumor growth.																	

### REFERENCES

---

[1]. Meina Liang, et al. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy. AAPS J. 2020 Nov 18;23(1):4.

[2]. Naomi Laing, et al. Inhibition of platelet-derived growth factor receptor  $\alpha$  by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer. Mol Pharmacol. 2013 Jun;83(6):1247-56.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA